Status:
COMPLETED
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
Lead Sponsor:
AstraZeneca
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
18-69 years
Phase:
PHASE4
Brief Summary
The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in pa...
Eligibility Criteria
Inclusion
- metabolic syndrome (according to National Cholesterol Education Program (NCEP) Adenosine triphosphate (ATP) Ill criteria)
- LDL-Cholesterol \> 130mg/dl
- HDL-Cholesterol \< 40mg/dl in males and \<50mg/dl in females
- Triglycerides \< 400 mg/dl
Exclusion
- With a concomitant coronary disease
- Currently under statin therapy or previously treated with statins within the last 6 months
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT00815659
Start Date
December 1 2008
End Date
March 1 2010
Last Update
August 31 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research site
Ankara, Besevler, Turkey (Türkiye)
2
Research site
Kayseri, Erciyes, Turkey (Türkiye)
3
Research site
Istanbul, Haseki, Turkey (Türkiye)
4
Research site
Kocaeli, Umuttepe, Turkey (Türkiye)